Essentials in lung transplantation. (2018)

• Record Type: Book
• Further Information: Note: Allan R. Glanville, editor.
• Editors: Glanville, Allan R
• Contents: Intro; Preface; Contents; Chapter 1: Who and When to Transplant: What Has Changed?; 1.1 Introduction; 1.2 General Inclusion and Exclusion Criteria for Lung Transplantation; 1.3 Special Considerations for Lung Transplantation; 1.3.1 Nutritional Status; 1.3.2 Frailty and Sarcopaenia; 1.3.3 Malignancy; 1.3.4 Mechanical Bridge to Transplantation Including Extracorporeal Life Support (ECLS); 1.3.5 Pulmonary Artery Hypertension (PAH); 1.4 Specific Clinical Condition Criteria; 1.4.1 Chronic Obstructive Pulmonary Disease; 1.4.2 Interstitial Lung Disease (ILD); 1.4.2.1 Special Considerations 1.4.3 Cystic Fibrosis (CF)1.4.3.1 Specific Considerations; 1.4.4 Pulmonary Vascular Diseases; 1.5 Lung Retransplantation; References; Chapter 2: Surgical Approaches: Tricks of the Trade; 2.1 Introduction; 2.2 Transplant Listing; 2.3 Donor Management and Surgical Organ Retrieval; 2.4 Recipient Surgery; 2.4.1 Peri-operative Extracorporeal Support; 2.4.2 Downsizing Lungs; 2.4.3 Bilateral Sequential Lung Transplantation; 2.4.4 Single Lung Transplantation; 2.4.5 Heart-Lung Transplantation; 2.5 Conclusion; References Chapter 3: Donation After Brain Death Versus Donation After Circulatory Death Donors in Lung Transplantation: Are They Different?3.1 Introduction; 3.2 The Key Features of DBD LTx; 3.3 The Key Features of DCD LTx; 3.4 The Utility and Outcomes of DBD versus DCD LTx in Australia; 3.5 Potential for Increasing DBD LTx Donor Numbers; 3.6 Potential for Increasing DCD LTx Donor Numbers; 3.7 Conclusion; References; Chapter 4: ECMO and EVLP; 4.1 Introduction; 4.2 Circulatory Set Up of ECMO Support; 4.3 Indications for VV ECMO; 4.4 Complications of VV ECMO Therapy 4.5 Outcome of VV ECMO Use for Respiratory Failure4.6 Ex-Vivo Lung Perfusion; 4.6.1 Introduction; 4.6.2 Assessment of Marginal Donor Lungs; 4.6.3 Outcome; References; Chapter 5: Immunosuppression: Have We Learnt Anything; 5.1 Introduction; 5.2 The Immune System and the Lung Allograft; 5.3 Current Practices; 5.4 The Induction Phase; 5.4.1 Types of Induction Agents and Their Use; 5.5 The Maintenance Phase; 5.5.1 Calcineurin Inhibitors; 5.5.2 The Cell Cycle Inhibitors; 5.5.3 Mammalian Target of Rapamycin (mTOR) Inhibitors; 5.5.3.1 The Use of mTOR Inhibitors in Special Situations 5.5.4 The Use of Azithromycin5.6 Therapeutic Drug Monitoring and Adherence; 5.7 Conclusion; References; Chapter 6: Cellular Rejection: Is it Still Relevant?; 6.1 Introduction; 6.2 Risk Factors; 6.3 Clinical Features; 6.4 Monitoring for Rejection; 6.4.1 Determining Rejection; 6.4.2 Lung Function Testing; 6.4.3 Pathological Testing; 6.4.4 Radiology; 6.4.5 Bronchoscopy; 6.5 Pathology; 6.5.1 Prevalence of Rejection; 6.5.2 Treatment; 6.5.3 Outcomes; References; Chapter 7: Antibody Mediated Rejection: Are We There Yet?; 7.1 Pre-transplant Sensitization; 7.2 Clinical Diagnosis of AMR
• Publisher Details: Cham : Springer
• Publication Date: 2018
• Extent: 1 online resource
• Subjects: 617.5420592; Medicine; Lungs -- Transplantation; MEDICAL / Surgery / General; Medical -- Pulmonary & Thoracic Medicine; Respiratory medicine; Thoracic surgery; Pneumology; Medical -- Surgery -- Thoracic; Cardiothoracic surgery; Electronic books
• Languages: English
• ISBNs: 9783319909332; 3319909339
• Related ISBNs: 9783319909325; 3319909320
• Notes: Note: Online resource; title from PDF title page (EBSCO, viewed September 6, 2018)
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.